Abstract

Technological innovation is transforming traditional clinical practice, enabling people with multiple sclerosis (pwMS) to contribute health care outcome data remotely between clinic visits. In both relapsing and progressive forms of multiple sclerosis (MS), patients may experience variable disability accrual and symptoms throughout their disease course. The potential impact on the quality of life (QoL) in pwMS and their families and carers is profound. The introduction of treatment targets, such as NEDA (no evidence of disease activity) and NEPAD (no evidence of progression or active disease), that guide clinical decision-making, highlight the importance of utilizing sensitive instruments to measure and track disease activity and progression. However, the gold standard neurological disability tool—expanded disability severity scale (EDSS)—has universally recognized limitations. With strides made in our understanding of MS pathophysiology and DMT responsiveness, maintaining the status quo of measuring disability progression is no longer the recommended option. Outside the clinical trial setting, a comprehensive monitoring system has not been robustly established for pwMS. A 21st-century approach is required to integrate clinical, paraclinical, and patient-reported outcome (PRO) data from electronic health records, local databases, and patient registries. Patient and public involvement (PPI) is critical in the design and implementation of this workflow. To take full advantage of the potential of digital technology in the monitoring and care and QoL of pwMS will require iterative feedback between pwMS, health care professionals (HCPs), scientists, and digital experts.

Highlights

  • Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and degenerative disease of the central nervous system (CNS)

  • Optimizing the landscape of individualized, effective, and compassionate care with and for people with MS (pwMS) remains a work in progress

  • Whereas clinical trials provide data on a cohort level, the evidence produced can only provide a backdrop for decisions that need to be tailored to the individual pwMS

Read more

Summary

INTRODUCTION

Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and degenerative disease of the central nervous system (CNS). While clinical trials usually allocate sufficient time to complete and fully document an EDSS (which takes ∼20– 30 min), the time constraints of clinical practice regularly lead to either an “estimated” EDSS, or systematic clinical assessments remain patchy, or are not undertaken at all [11] To overcome this shortcoming, various versions of a patient-reported EDSS (PREDSS) have been proposed. Given a clinical and research focus of BartsMS on advanced MS, i.e., people with an EDSS of ≥ 6.5 [25], the ABILHAND questionnaire is regularly administered to capture perceived manual ability [26] Obtaining such “real world” outcome measures in routine clinical practice and trials has been recognized by the European Medicines Agency (EMA) as an important component of disease management [27]. Wearable technologies, including motion detecting devices (MTDs) and smartphone applications may facilitate minimally intrusive assessment of outcomes such as step count, walking speed, and gait [37] and support neurorehabilitation [38]

A MODEL OF INTEGRATED MONITORING AND PATIENT ENGAGEMENT
DISCUSSION
DATA AVAILABILITY STATEMENT
Multiple Sclerosis
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call